What is claimed is:

1. A humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region (V_H) comprising three heavy chain CDRs as set forth in SEQ ID NOs: 9-11, and a light chain variable region (VL) comprising three CDRs as set forth in SEQ ID NOs: 22-24; and
wherein the V_H comprises: an amino acid sequence of SEQ ID NO: 1 (EVQLXESGGGLVQPGGSLRLSCXASGFTFSNFWMNWVRQAPGKGLEWVXE IRLKSNNYATHYAESVKGRFTISRDDSKXXLYLQMNSLXTEDTXVYYCTSYD YEYWGQGTLVTVSA), wherein the X at position i (i =5, 23, 49, 79, 80, 89, 94) of SEQ ID NO: 1 is referred as X_{Hi}, wherein X_{H5} is V or L, X_{H23} is A or S, X_{H49} is S, A or G, X_{H79} is N or S, X_{H80} is T or I, X_{H89} is K or R, and X_{H94} is A or T;
wherein the V_L comprises an amino acid sequence of SEQ ID NO: 2 (DIQMTQSPXXLSXSVGDRVTXXCKASENVGTYVSWYQQKPGXXPKLLIYGA SNRYTGVPXRFTGXGSGTDFTLTISSLQXXDXATYYCGQSYSYPFTFGSGTKL EIK), wherein the X at position j (j =9, 10, 13, 21, 22, 42, 43, 60, 65, 80, 81, 83) of SEQ ID NO: 2 is referred as X_{Lj}, wherein X_{L9} is S, P or A, X_{L10} is T or S, X_{L13} is A, L or V, X_{L21} is L or I, X_{L22} is S or T, X_{L42} is K or Q, XL_{43} is A, T or S, X_{L60} is S or A, X_{L65} is S or T, X_{L80} is P or S, X_{L81} is E or D, and X_{L83} is F or I.

2. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein (a) X_{H5} is V, X_{H23} is A; and/or (b), X_{H49} is S or A; and/or (c) X_{H79} is N, X_{H80} is T, X_{H89} is K or R, X_{H94} is A.

3. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein the V_H comprises an amino acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7.

4. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein (a) X_{L9} is S or A, X_{L10} is T or S, X_{L13} is A, X_{L21} is L or I, X_{L22} is S or T; and/or (b) X_{L42} is K or Q, X_{L43} is A or T; and/or (c) X_{L60} is S, X_{L65} is S or T, X_{L80} is P, X_{L81} is E or D, X_{L83} is F.

5. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein the V_L comprises an amino acid sequence of SEQ ID NO:16, SEQ ID NO:18 or SEQ ID NO:20.

6. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein the antigen binding fragment is an antibody fragment selected from $F(ab')_2$, Fab', Fab, Fv, scFv, dsFv, dAb, and a single chain binding polypeptide.

7. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain polypeptide comprises a constant region of human IgG heavy chain.

8. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 7, wherein the human IgG is human IgG2.

9. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein the light chain polypeptide comprises a constant region of human κ chain.

10. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 1, wherein the humanized anti-BASIGIN antibody or antigen binding fragment thereof binds to BASIGIN with a K_D between about 1×10^{-11}M and about 5×10^{-10}M.

11. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of claim 10, wherein the humanized anti-BASIGIN antibody or antigen binding fragment thereof binds to BASIGIN with a K_D between 5×10^{-11}M and about 1.1×10^{-10}M.

12. An isolated nucleic acid sequence encoding the humanized anti-BASIGIN antibody or antigen binding fragment thereof of any one of claims 1-11.

13. The isolated nucleic acid sequence of claim 12, which comprises a nucleotide sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:17, SEQ ID

NO:19, or SEQ ID NO:21, or a nucleotide acid sequence having at least 90% sequence identity thereof.

14. The isolated nucleic acid sequence of claim 12, which further comprises a nucleotide sequence encoding a constant region of human IgG heavy chain or human kappa chain.

15. A vector comprising the nucleic acid sequence of any one of claims 12-14.

16. A host cell comprising the vector of claim 15.

17. The host cell of claim 16, wherein the cell is CHO cell.

18. A composition comprising (a) the humanized anti-BASIGIN antibody or antigen binding fragment thereof of any one of claims 1-11, and (b) a pharmaceutically acceptable carrier.

19. The humanized anti-BASIGIN antibody or antigen binding fragment thereof of any one of claims 1-11 or the composition of claim 18 for use in the treatment of a BASIGIN related disease in a subject, wherein an effective amount of the humanized anti-BASIGIN antibody or antigen binding fragment thereof or the composition is to be administered to the subject.

20. The humanized anti-BASIGIN antibody or antigen binding fragment thereof or the composition of claim 19, wherein the BASIGIN related disease is cancer or malaria.

21. The humanized anti-BASIGIN antibody or antigen binding fragment thereof or the composition of claim 20, wherein the cancer is lung cancer, liver cancer, cervical cancer, colon cancer, breast cancer, ovarian cancer, esophageal cancer or gastric cancer.

22. The humanized anti-BASIGIN antibody or antigen binding fragment thereof or the composition of claim 19, wherein the subject is human.

23. Use of the humanized anti-BASIGIN antibody or antigen binding fragment thereof of any one of claims 1-11 or the composition of claim 18 in the manufacture of a medicament for treating a BASIGIN related disease in a subject.

24. The use of claim 23, wherein the BASIGIN related disease is cancer or malaria.

25. The use of claim 24, wherein the cancer is lung cancer, liver cancer, cervical cancer, colon cancer, breast cancer, ovarian cancer, esophageal cancer or gastric cancer.

26. The use of claim 23, wherein the subject is human.